159 related articles for article (PubMed ID: 34080070)
1. From Lab Formulation Development to CTM Manufacturing of KO-947 Injectable Drug Products: a Case Study and Lessons Learned.
Deng X; Ren P; Mai W; Wang Y; Zhang Y; Wu H; Xie Y; Chen H
AAPS PharmSciTech; 2021 Jun; 22(5):168. PubMed ID: 34080070
[TBL] [Abstract][Full Text] [Related]
2. Formulation and Stability of Solutions.
Akers MJ
Int J Pharm Compd; 2016; 20(1):41-5. PubMed ID: 27127830
[TBL] [Abstract][Full Text] [Related]
3. Overview of drug product development.
Narayan P
Curr Protoc Pharmacol; 2011 Dec; Chapter 7():Unit 7.3.1-29. PubMed ID: 22147349
[TBL] [Abstract][Full Text] [Related]
4. Development of a lyophilised RH1 formulation: a novel DT diaphorase activated alkylating agent.
Elliott MA; Ford SJ; Walker AA; Hargreaves RH; Halbert GW
J Pharm Pharmacol; 2002 Apr; 54(4):487-92. PubMed ID: 11999125
[TBL] [Abstract][Full Text] [Related]
5. The improved dissolution and prevention of ampoule breakage attained by the introduction of pretreatment into the production process of the lyophilized formulation of recombinant human Interleukin-11 (rhIL-11).
Hirakura Y; Kojima S; Okada A; Yokohama S; Yokota S
Int J Pharm; 2004 Nov; 286(1-2):53-67. PubMed ID: 15501002
[TBL] [Abstract][Full Text] [Related]
6. Novel strategies for the formulation and processing of poorly water-soluble drugs.
Göke K; Lorenz T; Repanas A; Schneider F; Steiner D; Baumann K; Bunjes H; Dietzel A; Finke JH; Glasmacher B; Kwade A
Eur J Pharm Biopharm; 2018 May; 126():40-56. PubMed ID: 28532676
[TBL] [Abstract][Full Text] [Related]
7. Translational formulation of nanoparticle therapeutics from laboratory discovery to clinical scale.
Feng J; Markwalter CE; Tian C; Armstrong M; Prud'homme RK
J Transl Med; 2019 Jun; 17(1):200. PubMed ID: 31200738
[TBL] [Abstract][Full Text] [Related]
8. Long-term stability of morphine hydrochloride in 0.9% NaCl infusion polyolefin bags after freeze-thaw treatment and in polypropylene syringes at 5 degrees C + 3 degrees C.
Hecq JD; Godet M; Gillet P; Jamart J; Galanti L
Int J Pharm Compd; 2014; 18(1):78-82. PubMed ID: 24881344
[TBL] [Abstract][Full Text] [Related]
9. Process analytical technologies and injectable drug products: Is there a future?
Henriques J; Sousa J; Veiga F; Cardoso C; Vitorino C
Int J Pharm; 2019 Jan; 554():21-35. PubMed ID: 30389475
[TBL] [Abstract][Full Text] [Related]
10. The Importance of Understanding the Freezing Step and Its Impact on Freeze-Drying Process Performance.
Assegehegn G; Brito-de la Fuente E; Franco JM; Gallegos C
J Pharm Sci; 2019 Apr; 108(4):1378-1395. PubMed ID: 30529167
[TBL] [Abstract][Full Text] [Related]
11. Formulation Screening and Freeze-Drying Process Optimization of Ginkgolide B Lyophilized Powder for Injection.
Liu D; Galvanin F; Yu Y
AAPS PharmSciTech; 2018 Feb; 19(2):541-550. PubMed ID: 28849380
[TBL] [Abstract][Full Text] [Related]
12. A combined mathematical model linking the formation of amorphous solid dispersions with hot-melt-extrusion process parameters.
Schittny A; Ogawa H; Huwyler J; Puchkov M
Eur J Pharm Biopharm; 2018 Nov; 132():127-145. PubMed ID: 30240820
[TBL] [Abstract][Full Text] [Related]
13. Inhomogeneous Distribution of Components in Solid Protein Pharmaceuticals: Origins, Consequences, Analysis, and Resolutions.
Nguyen KTT; Frijlink HW; Hinrichs WLJ
J Pharm Sci; 2020 Jan; 109(1):134-153. PubMed ID: 31606540
[TBL] [Abstract][Full Text] [Related]
14. Pharmaceutical development of a parenteral lyophilised dosage form for the novel anticancer agent C1311.
Den Brok MW; Nuijen B; Kettenes-Van Den Bosch JJ; Van Steenbergen MJ; Buluran JN; Harvey MD; Grieshaber CK; Beijnen JH
PDA J Pharm Sci Technol; 2005; 59(5):285-97. PubMed ID: 16316064
[TBL] [Abstract][Full Text] [Related]
15. Stability of buffer-free freeze-dried formulations: A feasibility study of a monoclonal antibody at high protein concentrations.
Garidel P; Pevestorf B; Bahrenburg S
Eur J Pharm Biopharm; 2015 Nov; 97(Pt A):125-39. PubMed ID: 26455339
[TBL] [Abstract][Full Text] [Related]
16. Fundamentals of freeze-drying.
Nail SL; Jiang S; Chongprasert S; Knopp SA
Pharm Biotechnol; 2002; 14():281-360. PubMed ID: 12189727
[TBL] [Abstract][Full Text] [Related]
17. Nanoamorphous drug products - Design and development.
Jog R; Burgess DJ
Int J Pharm; 2018 Dec; 553(1-2):238-260. PubMed ID: 30359685
[TBL] [Abstract][Full Text] [Related]
18. Basic Principles of Lyophilization, Part 2.
Akers MJ
Int J Pharm Compd; 2016; 20(1):20-7. PubMed ID: 27125053
[TBL] [Abstract][Full Text] [Related]
19. Use of a temperature ramp approach (TRA) to design an optimum and robust freeze-drying process for pharmaceutical formulations.
Assegehegn G; Brito-de la Fuente E; Franco JM; Gallegos C
Int J Pharm; 2020 Mar; 578():119116. PubMed ID: 32027958
[TBL] [Abstract][Full Text] [Related]
20. Drug stability testing and formulation strategies.
Wu Z
Pharm Dev Technol; 2018 Dec; 23(10):941. PubMed ID: 31284808
[No Abstract] [Full Text] [Related]
[Next] [New Search]
